Latest & greatest articles for olmesartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on olmesartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on olmesartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for olmesartan

1. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension

Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with hydrochlorothiazide (OLM/HCTZ). One analysis pooled 1,610 patients from two 6

Full Text available with Trip Pro

2018 EvidenceUpdates

2. Olmesartan

Olmesartan Top results for olmesartan - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for olmesartan The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

3. Hypertension: avoid olmesartan pending its withdrawal

Hypertension: avoid olmesartan pending its withdrawal Prescrire IN ENGLISH - Spotlight ''Hypertension: avoid olmesartan pending its withdrawal'', 1 May 2016 {1} {1} {1} | | > > > Hypertension: avoid olmesartan pending its withdrawal Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Hypertension: avoid olmesartan pending its withdrawal Olmesartan (...) exposes patients to increased, and sometimes severe, gastrointestinal adverse effects. It is in the best interest of patients not to use it. Olmesartan, commercialised for hypertension, is no more effective than the other sartans or than ACEs (angiotensin-converting enzyme inhibitors) against the cardiovascular complications of hypertension. Since mid-2012, excessive, sometimes severe, gastrointestinal adverse effects (enteropathies) with diarrhoea, sometimes intense abdominal pains, weight loss, etc

2016 Prescrire

4. Sprue-Like Enteropathy Associated With Olmesartan: A New Kid on the Enteropathy Block (PubMed)

Sprue-Like Enteropathy Associated With Olmesartan: A New Kid on the Enteropathy Block 28868435 2018 11 13 2341-4545 23 2 2016 Mar-Apr GE Portuguese journal of gastroenterology GE Port J Gastroenterol Sprue-Like Enteropathy Associated With Olmesartan: A New Kid on the Enteropathy Block. 61-65 10.1016/j.jpge.2016.02.005 Hujoel Isabel A IA Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. Rubio-Tapia Alberto A Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

Full Text available with Trip Pro

2016 GE Portuguese journal of gastroenterology

5. Olmesartan-Induced Sprue Like Enteropathy (PubMed)

Olmesartan-Induced Sprue Like Enteropathy Chronic diarrhoea is a common clinical problem in gastroenterology practice and often it is difficult to diagnose the cause. Villous atrophy is not specific and the rarer possibility of drug-induced enteritis should always be considered. Olmesartan has recently been described as a cause of drug-induced enteropathy characterized by chronic diarrhoea and varying degrees of duodenal mucosa atrophy resembling celiac disease. We describe two cases of sprue (...) -like enteropathy in patients treated with olmesartan for arterial hypertension several years before the onset of symptoms. Patients presented severe diarrhoea and significant weight loss, and both had histological evidence of intestinal villous atrophy. The clinical signs completely resolved after drug withdrawal. Olmesartan-induced enteropathy is a new clinical entity that must be included in the differential diagnosis of villous atrophy with negative celiac serology. The clinical and histological

Full Text available with Trip Pro

2016 GE Portuguese journal of gastroenterology

6. Enteropathy Associated with Olmesartan (PubMed)

Enteropathy Associated with Olmesartan The recognition of an enteropathy caused by olmesartan is recent. It was first described in 2012 by the Mayo Clinic, which presented 22 clinical cases. Olmesartan is a highly prescribed drug and the differential diagnosis of a sprue-like enteropathy is very wide, so it is important to be aware of this pathology. We report a case of a 67-years-old man, with arterial hypertension under treatment with olmesartan, with a 4-months history of diarrhea and weight (...) lost. He was admitted three times in our Department during this period of time. An initial diagnosis was made of lymphocytic colitis but he did not respond to treatment with corticosteroids. There was a high suspicion of celiac disease, so the patient started a gluten-free diet but still there were no symptomatic changes. The patient underwent several blood and imaging tests which were negative. Due to the suspicion of an enteropathy caused by drugs, olmesartan was stopped and the patient showed

Full Text available with Trip Pro

2015 GE Portuguese journal of gastroenterology

7. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study (PubMed)

Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study Severe sprue-like enteropathy associated with olmesartan has been reported, but there has been no demonstration of an increased risk by epidemiological studies.To assess, in a nationwide patient cohort, the risk of hospitalisation for intestinal malabsorption associated with olmesartan compared with other angiotensin receptor blockers (ARB) and ACE inhibitors (ACEIs).From the French (...) , the adjusted rate ratio of hospitalisation with a discharge diagnosis of intestinal malabsorption was 2.49 (95% CI 1.73 to 3.57, p<0.0001) in olmesartan users. This adjusted rate ratio was 0.76 (95% CI 0.39 to 1.49, p=0.43) for treatment duration shorter than 1 year, 3.66 (95% CI 1.84 to 7.29, p<0.001) between 1 and 2 years and 10.65 (95% CI 5.05 to 22.46, p<0.0001) beyond 2 years of exposure. Median length of hospital stay for intestinal malabsorption was longer in the olmesartan group than in the other

2015 EvidenceUpdates

8. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis

Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

9. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. (PubMed)

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. Microalbuminuria is an early predictor of diabetic nephropathy and premature cardiovascular disease. We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria.In a randomized, double-blind, multicenter, controlled trial, we assigned 4447 patients with type 2 diabetes to receive olmesartan (...) (at a dose of 40 mg once daily) or placebo for a median of 3.2 years. Additional antihypertensive drugs (except angiotensin-converting-enzyme inhibitors or ARBs) were used as needed to lower blood pressure to less than 130/80 mm Hg. The primary outcome was the time to the first onset of microalbuminuria. The times to the onset of renal and cardiovascular events were analyzed as secondary end points.The target blood pressure (<130/80 mm Hg) was achieved in nearly 80% of the patients taking olmesartan

Full Text available with Trip Pro

2011 NEJM

10. Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens

Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens Choice of angiotensin receptor blocker in moderate hypertension: a UK-based costbenefit comparison of olmesartan- and candesartan-based regimens Belsey JD Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim of the study was to compare mean costs per patient of target-driven hypertension treatment using olmesartan with the same approach using candesartan in patients with previously untreated moderate hypertension in the UK. The authors

2011 NHS Economic Evaluation Database.

11. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis (PubMed)

Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis The aim of this study was to evaluate the impact of olmesartan on progression of coronary atherosclerosis.Prior intravascular ultrasound (IVUS) trial results suggest slowing of coronary atheroma progression with some medicines but have not shown convincing evidence of regression with angiotension-II (...) receptor blocking agents.A prospective, randomized, multicenter trial-OLIVUS (Impact of OLmesartan on progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound)-was performed in 247 stable angina pectoris patients with native coronary artery disease. When these patients underwent percutaneous coronary intervention for culprit lesions, IVUS was performed in their nonculprit vessels (without angiographically documented coronary stenosis [<50%]). Patients were randomly assigned

Full Text available with Trip Pro

2010 EvidenceUpdates

12. Tribenzor (olmesartan medoxomil / amlodipine / hydrochlorothiazide)

Tribenzor (olmesartan medoxomil / amlodipine / hydrochlorothiazide) Drug Approval Package: TRIBENZOR (olmesartan medoxomil and amlodipine) NDA #200175 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - TRIBENZOR (olmesartan medoxomil / amlodipine / hydrochlorothiazide) Tablets Company: Daiichi Sankyo, Inc. Application No.: 200175 Approval Date: 07/23/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2010 FDA - Drug Approval Package

13. Olmesartan medoxomil - Hypertension

Olmesartan medoxomil - Hypertension Common Drug Review CEDAC Meeting – April 15, 2009 Page 1 of 2 Notice of CEDAC Final Recommendation – May 27, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION OLMESARTAN MEDOXOMIL (Olmetec ® – Schering-Plough Canada Inc.) Indication: Mild to Moderate Essential Hypertension Description: Olmesartan is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. Dosage Forms: Supplied (...) as 20 mg and 40 mg tablets. The recommended starting dose of olmesartan is 20 mg once daily when used as monotherapy and may be increased to 40 mg daily. Recommendation: The Canadian Expert Drug Advisory Committee recommends that olmesartan be listed in a similar manner as drug plans list other ARBs. Reasons for the Recommendation: 1. Results from double-blind randomized controlled trials demonstrate similar reductions in systolic and diastolic blood pressure between olmesartan and other angiotensin

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

14. Olmesartan medoxomil + hydrochlorothiazide - Hypertension

Olmesartan medoxomil + hydrochlorothiazide - Hypertension Common Drug Review CEDAC Meeting – April 15, 2009 Page 1 of 2 Notice of CEDAC Final Recommendation – May 27, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION OLMESARTAN MEDOXOMIL /HYDROCHLOROTHIAZIDE (Olmetec Plus ® – Schering-Plough Canada Inc.) Indication: Mild to Moderate Essential Hypertension Description: Olmetec Plus is a combination product containing an angiotensin II receptor blocker (ARB), olmesartan (...) , and a thiazide diuretic, hydrochlorothiazide. Olmetec Plus is indicated for the treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate. It is not indicated for the initial treatment of hypertension and patients should be titrated to a stable dose of the individual components prior to initiation of therapy with Olmetec Plus. Dosage Forms: Suppled as tablets containing olmesartan medoxomil/hydrochlorothiazide in the following ratio: 20 mg/12.5 mg, 40 mg

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review